Complement-blocking medications like Soliris (eculizumab) can be effective for controlling atypical hemolytic uremic syndrome (aHUS) in patients carrying a genetic variant called the MCPggaac haplotype, a new study reports. Researchers in Southeastern Europe reviewed the cases of 14 children in the region with aHUS to determine the best…

Genetic screening of a large group of people suspected of having atypical hemolytic uremic syndrome (aHUS) detected very few gene variants likely to be associated with the condition, a study reported. Despite signs of aHUS, around two-thirds of those tested had no evidence of any known disease-causing variants. These…

A substantial number of people with atypical hemolytic uremic syndrome (aHUS) carry rare structural variations in a part of the genome called the CFH-CFHR region and some variants are linked to certain disease manifestations, a recent study reports. “This work highlights the association between aHUS and genomic rearrangements in…

Disease-causing variants in complement genes appear to be uncommon in children with atypical hemolytic uremic syndrome (aHUS) caused by autoantibodies against complement factor H (CFH), an Indian study found. The study, “Variants in complement genes are uncommon in patients with anti-factor H autoantibody-associated atypical hemolytic uremic syndrome,” was published…

A common mutation in the CD46 gene associated with atypical hemolytic uremic syndrome (aHUS) onset does not seem to be enough to trigger the disorder, as it occurs in both affected and unaffected family members, a genetic analysis shows.  Further analysis found evidence of an…

Rare genetic variants in complement genes have been associated with atypical hemolytic uremic syndrome (aHUS) linked with anti-factor H autoantibodies (anti-FHs), recent research shows. Moreover, the study adds evidence that common infections contribute to this type of aHUS in genetically predisposed individuals. These observations explain why there is a…